Evotec SE (EVT.DE)
EUR 8.5
(-4.23%)
EUR 8.5
(-4.23%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 222.55 Million EUR | 84.15% |
| 2022 | 153.21 Million EUR | 39.46% |
| 2021 | 109.86 Million EUR | 48.51% |
| 2020 | 73.97 Million EUR | 26.72% |
| 2019 | 58.37 Million EUR | 18.6% |
| 2018 | 49.22 Million EUR | 12.15% |
| 2017 | 43.89 Million EUR | 101.29% |
| 2016 | 21.8 Million EUR | -46.18% |
| 2015 | 40.51 Million EUR | 48.77% |
| 2014 | 27.23 Million EUR | 0.68% |
| 2013 | 27.05 Million EUR | -11.94% |
| 2012 | 30.72 Million EUR | 0.24% |
| 2011 | 30.64 Million EUR | 12.81% |
| 2010 | 27.16 Million EUR | -28.57% |
| 2009 | 38.03 Million EUR | -39.76% |
| 2008 | 63.13 Million EUR | 10.3% |
| 2007 | 57.23 Million EUR | 6.49% |
| 2006 | 53.74 Million EUR | 48.23% |
| 2005 | 36.25 Million EUR | 212.61% |
| 2004 | -32.19 Million EUR | 12.32% |
| 2003 | -36.72 Million EUR | -53.58% |
| 2002 | -23.91 Million EUR | -87.72% |
| 2001 | -12.73 Million EUR | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 58.98 Million EUR | -5.14% |
| 2024 Q1 | 62.17 Million EUR | -0.18% |
| 2023 Q2 | 82.61 Million EUR | 102.87% |
| 2023 Q4 | 62.29 Million EUR | 24.58% |
| 2023 Q1 | 40.72 Million EUR | -9.04% |
| 2023 Q3 | 49.99 Million EUR | -39.48% |
| 2023 FY | 282.13 Million EUR | 84.15% |
| 2022 FY | 153.21 Million EUR | 39.46% |
| 2022 Q1 | 31.83 Million EUR | -14.27% |
| 2022 Q2 | 34.66 Million EUR | 8.9% |
| 2022 Q3 | 41.94 Million EUR | 21.01% |
| 2022 Q4 | 44.77 Million EUR | 6.72% |
| 2021 FY | 109.86 Million EUR | 48.51% |
| 2021 Q3 | 25.42 Million EUR | 8.66% |
| 2021 Q4 | 37.13 Million EUR | 46.02% |
| 2021 Q2 | 23.4 Million EUR | -2.08% |
| 2021 Q1 | 23.9 Million EUR | 19.07% |
| 2020 Q2 | 16.97 Million EUR | -1.2% |
| 2020 FY | 73.97 Million EUR | 26.72% |
| 2020 Q4 | 20.07 Million EUR | 1.61% |
| 2020 Q1 | 17.17 Million EUR | -4.11% |
| 2020 Q3 | 19.75 Million EUR | 16.4% |
| 2019 Q2 | 15.25 Million EUR | 21.08% |
| 2019 FY | 58.37 Million EUR | 18.6% |
| 2019 Q1 | 12.59 Million EUR | -8.84% |
| 2019 Q3 | 12.62 Million EUR | -17.25% |
| 2019 Q4 | 17.91 Million EUR | 41.94% |
| 2018 Q1 | 11.95 Million EUR | 9.89% |
| 2018 Q3 | 10.97 Million EUR | -12.07% |
| 2018 Q2 | 12.47 Million EUR | 4.36% |
| 2018 FY | 49.22 Million EUR | 12.15% |
| 2018 Q4 | 13.81 Million EUR | 25.93% |
| 2017 Q4 | 10.88 Million EUR | -23.55% |
| 2017 Q1 | 9.07 Million EUR | 424.7% |
| 2017 Q2 | 9.7 Million EUR | 7.0% |
| 2017 Q3 | 14.23 Million EUR | 46.63% |
| 2017 FY | 43.89 Million EUR | 101.29% |
| 2016 Q3 | 8.4 Million EUR | 6.52% |
| 2016 Q2 | 7.88 Million EUR | -5.08% |
| 2016 Q1 | 8.31 Million EUR | 1.0% |
| 2016 Q4 | -2.79 Million EUR | -133.25% |
| 2016 FY | 21.8 Million EUR | -46.18% |
| 2015 Q4 | 8.22 Million EUR | -25.47% |
| 2015 Q3 | 11.04 Million EUR | -2.54% |
| 2015 Q2 | 11.32 Million EUR | 14.16% |
| 2015 Q1 | 9.92 Million EUR | -6.21% |
| 2015 FY | 40.51 Million EUR | 48.77% |
| 2014 FY | 27.23 Million EUR | 0.68% |
| 2014 Q2 | 7.26 Million EUR | -10.3% |
| 2014 Q4 | 10.58 Million EUR | 713.85% |
| 2014 Q3 | 1.3 Million EUR | -82.1% |
| 2014 Q1 | 8.09 Million EUR | 76.86% |
| 2013 Q1 | 7.16 Million EUR | -29.67% |
| 2013 FY | 27.05 Million EUR | -11.94% |
| 2013 Q4 | 4.57 Million EUR | -39.14% |
| 2013 Q3 | 7.52 Million EUR | -3.4% |
| 2013 Q2 | 7.78 Million EUR | 8.61% |
| 2012 Q4 | 10.19 Million EUR | 44.17% |
| 2012 Q2 | 6.97 Million EUR | -13.4% |
| 2012 Q3 | 7.07 Million EUR | 1.39% |
| 2012 FY | 30.72 Million EUR | 0.24% |
| 2012 Q1 | 8.05 Million EUR | -5.39% |
| 2011 Q2 | 6.96 Million EUR | -16.73% |
| 2011 Q1 | 8.36 Million EUR | -24.68% |
| 2011 FY | 30.64 Million EUR | 12.81% |
| 2011 Q4 | 8.51 Million EUR | 12.31% |
| 2011 Q3 | 7.57 Million EUR | 8.86% |
| 2010 Q4 | 11.1 Million EUR | 115.32% |
| 2010 Q1 | 6.11 Million EUR | 952.15% |
| 2010 Q2 | 5.7 Million EUR | -6.61% |
| 2010 Q3 | 5.15 Million EUR | -9.7% |
| 2010 FY | 27.16 Million EUR | -28.57% |
| 2009 FY | 38.03 Million EUR | -39.76% |
| 2009 Q1 | 15.15 Million EUR | -18.07% |
| 2009 Q2 | 10.25 Million EUR | -32.35% |
| 2009 Q3 | 7.91 Million EUR | -22.84% |
| 2009 Q4 | 581 Thousand EUR | -92.65% |
| 2008 Q3 | 14.22 Million EUR | 1.5% |
| 2008 Q4 | 18.49 Million EUR | 29.99% |
| 2008 Q2 | 14.01 Million EUR | -14.59% |
| 2008 Q1 | 16.41 Million EUR | -34.19% |
| 2008 FY | 63.13 Million EUR | 10.3% |
| 2007 Q1 | - EUR | -100.0% |
| 2007 FY | 57.23 Million EUR | 6.49% |
| 2007 Q2 | -14.24 Million EUR | 0.0% |
| 2007 Q4 | 24.94 Million EUR | 71.58% |
| 2007 Q3 | 14.53 Million EUR | 202.09% |
| 2006 FY | 53.74 Million EUR | 48.23% |
| 2006 Q3 | 8.56 Million EUR | 2.21% |
| 2006 Q4 | 22.78 Million EUR | 165.92% |
| 2006 Q1 | 8.88 Million EUR | 5.93% |
| 2006 Q2 | 8.38 Million EUR | -5.7% |
| 2005 Q3 | - EUR | -100.0% |
| 2005 Q4 | 8.39 Million EUR | 0.0% |
| 2005 Q1 | 8.44 Million EUR | 31.91% |
| 2005 Q2 | 9.03 Million EUR | 6.99% |
| 2005 FY | 36.25 Million EUR | 212.61% |
| 2004 FY | -32.19 Million EUR | 12.32% |
| 2004 Q3 | - EUR | -100.0% |
| 2004 Q1 | 7.68 Million EUR | 16.62% |
| 2004 Q2 | 8.82 Million EUR | 14.88% |
| 2004 Q4 | 6.4 Million EUR | 0.0% |
| 2003 Q4 | 6.58 Million EUR | 10.79% |
| 2003 Q2 | - EUR | 0.0% |
| 2003 FY | -36.72 Million EUR | -53.58% |
| 2003 Q1 | - EUR | 0.0% |
| 2003 Q3 | 5.94 Million EUR | 0.0% |
| 2002 FY | -23.91 Million EUR | -87.72% |
| 2001 FY | -12.73 Million EUR | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| MPH Health Care AG | 4.22 Million EUR | -5171.917% |
| Apontis Pharma AG | 23.17 Million EUR | -860.522% |
| Dermapharm Holding SE | 142.51 Million EUR | -56.166% |
| MERCK Kommanditgesellschaft auf Aktien | 8.82 Billion EUR | 97.478% |
| PharmaSGP Holding SE | 50.72 Million EUR | -338.771% |
| SynBiotic SE | 1.5 Million EUR | -14673.987% |